ProQR Announces Upcoming Investor Conferences in April and May
20 avr. 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
18 avr. 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
29 mars 2023 08h00 HE
|
ProQR Therapeutics N.V.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early...
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
14 mars 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR to Present at Upcoming Scientific and Industry Conferences
07 mars 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
28 févr. 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
22 déc. 2022 06h15 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
Lilly and ProQR to Expand RNA Editing Collaboration
22 déc. 2022 06h00 HE
|
ProQR Therapeutics N.V.
INDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion...
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
14 nov. 2022 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Third Quarter 2022 Operating and Financial Results
09 nov. 2022 07h00 HE
|
ProQR Therapeutics N.V.
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event...